RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

J Natl Cancer Inst. 2023 Jun 8;115(6):762-763. doi: 10.1093/jnci/djad060.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Female
  • Humans
  • Maytansine* / therapeutic use
  • RNA, Messenger / genetics
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab / therapeutic use

Substances

  • Ado-Trastuzumab Emtansine
  • Receptor, ErbB-2
  • RNA, Messenger
  • Trastuzumab
  • Maytansine
  • ERBB2 protein, human